The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on CalciMedica's stock price. The endorsement reflects a bullish outlook on the company's future performance.